{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:35:46Z","timestamp":1761863746141,"version":"3.40.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ejca.2017.07.031","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T23:30:34Z","timestamp":1504654234000},"page":"39-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9455-6744","authenticated-orcid":false,"given":"Alain","family":"Ravaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Gomez-Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Quitterie","family":"Picat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Digue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Chevreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Gimbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Chauzit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9mi","family":"Sitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Cornelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Asselineau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Aziza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaury","family":"Daste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Quemener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Baud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9as","family":"Bikfalvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Pedenon\u2013P\u00e9richout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adela\u00efde","family":"Doussau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Molimard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Delord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.07.031_bib1","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/ncponc0342","article-title":"Angiogenic inhibitors: a new therapeutic strategy in oncology","volume":"2","author":"Gasparini","year":"2005","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ejca.2017.07.031_bib2","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical anti-angiogenesis and anti-tumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.07.031_bib3","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2017.07.031_bib4","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1158\/1078-0432.CCR-06-2254","article-title":"Targeting von Hippel-Lindau pathway in renal cell carcinoma","volume":"12","author":"Patel","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.07.031_bib5","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-08-2057","article-title":"mTOR inhibitor RAD001 (everolimus) has anti-angiogenic\/vascular properties distinct from a VEGFR tyrosine kinase inhibitor","volume":"15","author":"Lane","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2017.07.031_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2017.07.031_bib7","doi-asserted-by":"crossref","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Escudier","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.07.031_bib8","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1158\/1535-7163.MCT-06-0071","article-title":"The anti-tumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling","volume":"5","author":"Ikezoe","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2017.07.031_bib9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1349-7006.2006.00263.x","article-title":"Effect of SU11248 on gastrointestinal stromal tumour-T1 cells: enhancement of growth inhibition via inhibition of 3 kinase\/Akt\/mammalian target of rapamycin signaling","volume":"97","author":"Ikezoe","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ejca.2017.07.031_bib10","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1111\/j.1582-4934.2009.00692.x","article-title":"Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma","volume":"13","author":"Huynh","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ejca.2017.07.031_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3816\/CGC.2009.n.004","article-title":"Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma","volume":"7","author":"Patel","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2017.07.031_bib12","series-title":"Presented at: ASCO Annual Meeting; Chicago, IL","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies","author":"Patnaik","year":"2007"},{"key":"10.1016\/j.ejca.2017.07.031_bib13","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1002\/cncr.25931","article-title":"A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma","volume":"117","author":"Harzstark","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2017.07.031_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clgc.2011.11.002","article-title":"Phase I study of everolimus plus sorafenib for patients with advanced renal cell cancer","volume":"10","author":"Amato","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.ejca.2017.07.031_bib15","doi-asserted-by":"crossref","first-page":"18281","DOI":"10.1073\/pnas.1207759109","article-title":"Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors","volume":"109","author":"McTigue","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"year":"2006","series-title":"Common terminology criteria for adverse events (CTCAE) v30","author":"Cancer Therapy Evaluation Program","key":"10.1016\/j.ejca.2017.07.031_bib16"},{"key":"10.1016\/j.ejca.2017.07.031_bib17","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1200\/JCO.2010.31.9236","article-title":"Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?","volume":"29","author":"Postel-Vinay","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.07.031_bib18","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1016\/j.ejca.2014.04.030","article-title":"Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey","volume":"50","author":"Paoletti","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.07.031_bib19","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cca.2011.02.023","article-title":"Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC\/MS-MS","volume":"412","author":"Bouchet","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ejca.2017.07.031_bib20","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1200\/JCO.2007.14.0988","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumours","volume":"26","author":"O'Donnell","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.07.031_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumours","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2017.07.031_bib22","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/cncr.26429","article-title":"Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma","volume":"118","author":"Molina","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2017.07.031_bib23","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-13-0353","article-title":"Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2017.07.031_bib24","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s10637-015-0238-2","article-title":"Phase I combination of pazopanib and everolimus in PIK3CA mutation positive\/PTEN loss patients with advanced solid tumours refractory to standard therapy","volume":"33","author":"Rodrigues","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ejca.2017.07.031_bib25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/CAD.0b013e3283618b7b","article-title":"Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumours","volume":"24","author":"Semrad","year":"2013","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejca.2017.07.031_bib26","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"15","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.07.031_bib27","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumours: pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.07.031_bib28","unstructured":"EMEA public assessment report for afinitor. www.ema.europa.eu."},{"key":"10.1016\/j.ejca.2017.07.031_bib29","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","article-title":"Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial","volume":"14","author":"Rini","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2017.07.031_bib30","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.07.031_bib31","series-title":"Presented at: ASCO GU symposium; Orlando, FL","article-title":"A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts)","author":"McDermott","year":"2017"},{"key":"10.1016\/j.ejca.2017.07.031_bib32","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/annonc\/mdu516","article-title":"Designs of drug-combination phase I trials in oncology: a systematic review of the literature","volume":"26","author":"Rivi\u00e8re","year":"2015","journal-title":"Ann Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917311516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917311516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,2]],"date-time":"2022-08-02T07:02:21Z","timestamp":1659423741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917311516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":32,"alternative-id":["S0959804917311516"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.07.031","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I study of axitinib and everolimus in metastatic solid tumours and extension to metastatic renal cell carcinoma: Results of EVAX study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.07.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}